GlaxoSmithKline PLC
GSK | IL
Overview
Corporate Details
- ISIN(s):
- GB00BN7SWP63 (+1 more)
- LEI:
- 5493000HZTVUYLO1D793
- Country:
- United Kingdom
- Address:
- 79 NEW OXFORD STREET, WC1A 1DG LONDON
- Website:
- https://www.gsk.com/en-gb/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-25 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 563.3 KB | |
| 2025-06-24 16:30 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 60.7 KB | |
| 2025-06-24 16:00 |
Board/Management Change
Director Declaration
|
English | 5.6 KB | |
| 2025-06-24 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 668.9 KB | |
| 2025-06-23 18:50 |
Directors' Dealings
Replacement - Director/PDMR Shareholding
|
English | 85.6 KB | |
| 2025-06-23 16:30 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 84.5 KB | |
| 2025-06-23 09:30 |
Regulatory News Service
Replacement RNS: Linerixibat file accepted by EMA
|
English | 21.7 KB | |
| 2025-06-23 09:18 |
Regulatory News Service
GSK Submits Arexvy for adults 18+ with EMA
|
English | 21.7 KB | |
| 2025-06-23 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 875.2 KB | |
| 2025-06-20 08:00 |
Inside Information Statement
Arexvy filed in Japan for 18-49 at increased risk
|
English | 26.6 KB | |
| 2025-06-20 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 669.1 KB | |
| 2025-06-18 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 733.3 KB | |
| 2025-06-12 12:00 |
Directors' Dealings
GSK Plc - Director/PDMR Shareholding
|
English | 196.0 KB | |
| 2025-06-11 16:30 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 20.9 KB | |
| 2025-06-11 08:00 |
Transaction in Own Shares
Transaction in Own Shares
|
English | 654.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Valneva SE | France | VLA | |
|
VENTURE LIFE GROUP PLC | United Kingdom | VLG | |
|
Vetoquinol SA | France | VETO | |
|
Vicore Pharma Holding | Sweden | VICO | |
|
Vifor Pharma AG | Switzerland | VIFN | |
|
Vimian Group AB | Sweden | VIMIAN | |
|
Virbac | France | FR000 | |
|
Vistin Pharma | Norway | VISTN | |
|
Vivesto | Sweden | VIVE | |
|
Xlife Sciences AG | Switzerland | XLS |